Sep 30, 2026 8:05 am EDT Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration
Aug 12, 2026 4:05 pm EDT Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress
May 12, 2026 4:05 pm EDT Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress
Mar 16, 2026 4:05 pm EDT Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress
Jan 12, 2026 8:00 am EST Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)